Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ychou

Showing results (61-70 of 103) with videos related to

Pageof 11
Sort By:
Bulletin Du Cancer|November 1, 1995
[Prognostic factors of hepatocellular carcinoma: a multivariate analysis in 113 patients]M Ychou, M Veyrac, B Hanslik, et al.
American Journal of Clinical Oncology|April 25, 2000
Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II studyM Ychou, J Y Douillard, P Rougier, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Potential contribution of 131I-labelled monoclonal anti-CEA antibodies in the treatment of liver metastases from colorectal carcinomas: pretherapeutic study with dose recovery in resected tissuesM Ychou, M Ricard, J Lumbroso, et al.
American Journal of Clinical Oncology|June 17, 1998
A prospective randomized study comparing high- and low-dose leucovorin combined with same-dose 5-fluorouracil in advanced colorectal cancerM Ychou, P Fabbro-Peray, P Perney, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 2, 2009
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancerM Ychou, W Hohenberger, S Thezenas, et al.
Oncology|March 2, 2011
Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6G Perrocheau, J Bennouna, M Ducreux, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 1996
A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancerM Ychou, C Astre, P Rouanet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2009
Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature reviewR Le Scodan, F Mornex, N Girard, et al.
Cancer Chemotherapy and Pharmacology|September 29, 2007
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastasesM Ychou, F Viret, A Kramar, et al.
British Journal of Cancer|November 19, 2009
Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancerT Conroy, M Hebbar, J Bennouna, et al.
Pageof 11

Showing results (61-70 of 103) with videos related to

Sort By:
Pageof 11
Bulletin Du Cancer|November 1, 1995
[Prognostic factors of hepatocellular carcinoma: a multivariate analysis in 113 patients]M Ychou, M Veyrac, B Hanslik, et al.
American Journal of Clinical Oncology|April 25, 2000
Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II studyM Ychou, J Y Douillard, P Rougier, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Potential contribution of 131I-labelled monoclonal anti-CEA antibodies in the treatment of liver metastases from colorectal carcinomas: pretherapeutic study with dose recovery in resected tissuesM Ychou, M Ricard, J Lumbroso, et al.
American Journal of Clinical Oncology|June 17, 1998
A prospective randomized study comparing high- and low-dose leucovorin combined with same-dose 5-fluorouracil in advanced colorectal cancerM Ychou, P Fabbro-Peray, P Perney, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 2, 2009
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancerM Ychou, W Hohenberger, S Thezenas, et al.
Oncology|March 2, 2011
Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6G Perrocheau, J Bennouna, M Ducreux, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 1996
A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancerM Ychou, C Astre, P Rouanet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2009
Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature reviewR Le Scodan, F Mornex, N Girard, et al.
Cancer Chemotherapy and Pharmacology|September 29, 2007
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastasesM Ychou, F Viret, A Kramar, et al.
British Journal of Cancer|November 19, 2009
Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancerT Conroy, M Hebbar, J Bennouna, et al.
Pageof 11